Results 171 to 180 of about 310,541 (331)

Representative gross and microscopic pathology and immunohistochemical staining of the ablation zone 24-hours post-ablation in the orthotopic N1S1 HCC model.

, 2016
M. Thompson Scott, Callstrom Matthew R., Jondal Danielle E., A. Butters Kim, Knudsen Bruce E., Anderson Jill L., Lien Karen R., L. Sutor Shari, Lee Ju-Seog, S. Thorgeirsson Snorri, Grande Joseph P., Robert Lewis, Woodrum David A.   +12 more
openalex   +2 more sources

Targeted Degradation of eEF2K by a Structure‐Guided PROTAC Strategy for the Treatment of Triple‐Negative Breast Cancer

Advanced Science, EarlyView.
This study developed an eEF2K‐targeting PROTAC, A6, that efficiently degrades eEF2K in TNBC cells, inhibiting tumor growth in vitro and in vivo. To enhance tumor‐specific delivery, we engineered A6@ZIF‐8, a pH‐sensitive nanocarrier, which improved drug accumulation at tumor sites, offering a promising therapeutic strategy for TNBC through targeted ...
Shijun Cao, Changxin Zhong, Shilong Jiang, Yungui Li, Yang Xi, Mingxuan Xiao, Ting Jiang, Xiaoya Wan, Zonglin Chen, Xiaohui Yu, Yan Cheng   +10 more
wiley   +1 more source

IL‐31 levels correlate with pruritus in patients with cholestatic and metabolic liver diseases and is farnesoid X receptor responsive in NASH

Hepatology, EarlyView., 2022
IL‐31 levels correlate with pruritus in patients with cholestatic and metabolic liver diseases Abstract Background and Aims Pruritus is associated with multiple liver diseases, particularly those with cholestasis, but the mechanism remains incompletely understood.
Jun Xu, Ya Wang, Mina Khoshdeli, Matt Peach, Jen‐Chieh Chuang, Julie Lin, Wen‐Wei Tsai, Sangeetha Mahadevan, Wesley Minto, Lauri Diehl, Ruchi Gupta, Michael Trauner, Keyur Patel, Mazen Noureddin, Kris V. Kowdley, Aliya Gulamhusein, Christopher L. Bowlus, Ryan S. Huss, Robert P. Myers, Chuhan Chung, Andrew N. Billin   +20 more
wiley   +1 more source

Correction: Differential Inhibition of the TGF-β Signaling Pathway in HCC Cells Using the Small Molecule Inhibitor LY2157299 and the D10 Monoclonal Antibody against TGF-β Receptor Type II

, 2014
The PLOS ONE Staff
openalex   +2 more sources

HCC in metabolic syndrome: current concepts and future directions

, 2021
Lucia Zampaglione, Jacopo Ferrari, Federica Pedica, Nicolas Goossens   +3 more
openalex   +2 more sources

Engineered CAR‐NKT Extracellular Vesicles Suppress Tumor Progression and Enhance Antitumor Immunity

Advanced Science, EarlyView.
TM4SF1‐nanobody engineered CAR‐natural killer T–derived extracellular vesicles (CARTM4SF1‐EVs) provide a cell‐free alternative to CAR‐NKT therapy, achieving potent, targeted antitumor activity with reduced toxicity. CARTM4SF1‐EVs induce immunogenic cell death, remodel the tumor microenvironment, and enhance CD8⁺ T‐cell antitumor immunity.
Xiaopei Hao, Chengming Qu, Yanzhao Zhou, Xiaoqian Wang, Xiangjun Qian, Xun Chen, Feng Han, Xiaokai Zhang, Yiyi Ji, Han Li, ChengWei Ju, Peng Xia, Weiwei Tang, Hao Zhuang, Jinxue Zhou   +14 more
wiley   +1 more source

Proteogenomic characterization of cholangiocarcinoma

Hepatology, EarlyView., 2022
Proteogenomic characterization of cholangiocarcinoma with therapeutic strategies Abstract Background and Aims Cholangiocarcinoma (CCA) is a highly heterogeneous cancer with limited understanding and few effective therapeutic approaches. We aimed at providing a proteogenomic CCA characterization to inform biological processes and treatment ...
Mengjie Deng, Peng Ran, Lingli Chen, Yunzhi Wang, Zixiang Yu, Ke Cai, Jinwen Feng, Zhaoyu Qin, Yanan Yin, Subei Tan, Yang Liu, Chen Xu, Guoming Shi, Yuan Ji, Jian‐Yuan Zhao, Jian Zhou, Jia Fan, Yingyong Hou, Chen Ding   +18 more
wiley   +1 more source

Fatty liver disease is not associated with increased mortality in the elderly: A prospective cohort study

Hepatology, EarlyView., 2022
Graphical abstract summarizing the study design, main results and key findings Abstract Background and Aims Fatty liver disease (FLD) has been associated with excess mortality. Screening for hepatic steatosis (HS) in patients with metabolic dysfunction is therefore recommended by several guidelines, despite a paucity of evidence on the clinical ...
Laurens A. van Kleef, Milan J. Sonneveld, Maryam Kavousi, M. Arfan Ikram, Robert A. de Man, Robert J. de Knegt   +5 more
wiley   +1 more source

scRNA-Seq Analysis Revealed CAFs Regulating HCC Cells via PTN Signaling

Journal of Hepatocellular Carcinoma
Wenxian Lin,1– 4 Lizhu Tang,1,2,5 Chenyi Zhuo,1 Xiuli Mao,1– 4 Jiajia Shen,6 Shaoang Huang,3 Shangyang Li,3,7 Yujuan Qin,3,4 Ju Liao,2,3 Yuhong Chen,8 Xiamin Zhang,3,4 Yuting Li,9 Jian Song,4 Lingzhang Meng,4 Xiaofeng Dong,10 Yueyong Li2 1Key Laboratory ...
Lin W, Tang L, Zhuo C, Mao X, Shen J, Huang S, Li S, Qin Y, Liao J, Chen Y, Zhang X, Li Y, Song J, Meng L, Dong X, Li Y   +15 more
doaj  

P-178 Rego-Nivo II-III: Proof-of-concept phase II trial for the treatment of HCC refractory to chemotherapy after the 2nd line [PDF]

, 2021
Y. Ben Merabet, M. Lewin, Alina Pascale, Catherine Guettier, A. Laurent-Bellue, Emma Goldschmidt, J C Duclos-Vallée, Jean‐François Morère, Audrey Coilly, Didier Samuel, Olivier Rosmorduc   +10 more
openalex   +1 more source